Premium
Cardiac implications for the use of β 2 ‐adrenoceptor agonists for the management of muscle wasting
Author(s) -
Molenaar Peter,
Chen Lu,
Parsonage William A
Publication year - 2006
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0706670
Subject(s) - wasting , medicine , muscle hypertrophy , skeletal muscle , cardiac muscle , adrenergic receptor , cardiac hypertrophy , agonist , endocrinology , pharmacology , receptor
There are proposals for the implementation of β 2 ‐adrenoceptor agonists for the management of muscle wasting diseases. The idea has been initiated by studies in animal models which show that β 2 ‐adrenoceptor agonists cause hypertrophy of skeletal muscle. Their use in clinical practice will also need an understanding of possible effects of activation of human heart β 2 ‐adrenoceptors. Consequences could include an increased probability of arrhythmias in susceptible patients. British Journal of Pharmacology (2006) 147 , 583–586. doi: 10.1038/sj.bjp.0706670